Bioatla, Inc. (BCAB)
NASDAQ:BCAB
Want to see BCAB full AI Analyst Report?
BCAB Stock Chart & Stats
$0.19
-$0.03(-5.55%)
At close: 4:00 PM EST
$0.19
-$0.03(-5.55%)
Day’s Range― - ―
52-Week Range$3.26 - $71.50
Previous CloseN/A
Volume775.41K
Average Volume (3M)37.36K
Market Cap
$6.51M
Enterprise Value$9.09M
Total Cash (Recent Filing)$1.96M
Total Debt (Recent Filing)$6.09M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.72
Shares Outstanding1,656,926
10 Day Avg. Volume41,162
30 Day Avg. Volume37,362
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue4.54
Enterprise Value/Gross Profit4.29
Enterprise Value/Ebitda-0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary CAB PlatformBioAtla's Conditionally Active Biologic (CAB) platform is a durable competitive asset: tumor‑activated antibody selectivity can improve safety and therapeutic index, supporting differentiation, licensing discussions, and higher probability of partnering across multiple oncology indications over months.
Diversified Clinical PipelineMultiple programs at distinct stages (Phase 1 BA3182; planned Phase 3 for ozuriftamab vedotin) provide several non‑correlated development and commercialization pathways. That breadth increases chances of asset monetization or partnering during the strategic review, sustaining franchise value longer term.
Active Cost Cuts And Runway ManagementManagement has materially reduced operating costs and prioritized programs to extend runway, actions that cut recurring burn and preserve optionality. Combined with a standby equity facility and focused strategic review, these steps improve near‑term survivability and allow time to pursue licensing or asset sales.
Bears Say
Minimal Revenue And Heavy Cash BurnRevenue is negligible compared with persistent operating losses and large negative operating cash flow, indicating structural reliance on external financing. Over months this cash dynamic limits discretionary R&D, increases dilution risk, and constrains the ability to self‑fund pivotal trials.
Negative Shareholders' Equity And Shrinking AssetsThe shift to negative equity and a materially smaller asset base reduces financial flexibility and borrowing capacity. This structural balance‑sheet weakness impairs negotiating leverage with partners and heightens the need for dilutive financing or asset sales to sustain operations over the medium term.
Listing And Execution UncertaintyNasdaq review, major restructuring and leadership turnover create sustained execution and financing risk. Uncertainty around listing status and a failed financing channel structurally limits access to public and private capital and can delay trials or partnerships for several months.
BioAtla News
BCAB FAQ
What was Bioatla, Inc.’s price range in the past 12 months?
Bioatla, Inc. lowest stock price was $3.26 and its highest was $71.50 in the past 12 months.
What is Bioatla, Inc.’s market cap?
Bioatla, Inc.’s market cap is $6.51M.
When is Bioatla, Inc.’s upcoming earnings report date?
Bioatla, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Bioatla, Inc.’s earnings last quarter?
Currently, no data Available
Is Bioatla, Inc. overvalued?
According to Wall Street analysts Bioatla, Inc.’s price is currently Overvalued.
Does Bioatla, Inc. pay dividends?
Bioatla, Inc. does not currently pay dividends.
What is Bioatla, Inc.’s EPS estimate?
Bioatla, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioatla, Inc. have?
Bioatla, Inc. has 1,656,926 shares outstanding.
What happened to Bioatla, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bioatla, Inc.?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioatla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
Currently, No data available
---